Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
Public ClinicalTrials.gov record NCT04799249. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or second-line treatment for locally advanced unresectable/metastatic TNBC.
Study identification
- NCT ID
- NCT04799249
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 194 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 14, 2021 (Actual)
- Primary completion
- May 24, 2024 (Actual)
- Completion
- May 24, 2024 (Actual)
- Last update posted
- Aug 1, 2024
2021 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner M.D. Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Washington Cancer Institute at MedStar Washington Hospital Center - Oncology Research | Washington D.C. | District of Columbia | 20010 | — |
| Florida Cancer Specialists - North (SCRI) | St. Petersburg | Florida | 33705 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Maryland Oncology Hematology, P.A. | Clinton | Maryland | 20735 | — |
| Saint Luke's Cancer Specialists | Kansas City | Missouri | 64111 | — |
| Comprehensive Cancer Genetics of Nevada | Las Vegas | Nevada | 89128 | — |
| Duke Cancer Center | Durham | North Carolina | 27710 | — |
| UPC Pinnacle Health Cancer Institute | Pittsburgh | Pennsylvania | 15232 | — |
| Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Baptist Cancer Cancer - Oncology | Memphis | Tennessee | 38120 | — |
| Tennessee Oncology (SCRI) | Nashville | Tennessee | 37203 | — |
| Texas Oncology- Austin Central | Austin | Texas | 78731 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology P.A. | Tyler | Texas | 75702 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04799249, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 1, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04799249 live on ClinicalTrials.gov.